Two-photon spin injection in semiconductor

R. Bhat,P. Němec,Y. Kerachian,J. Sipe,H. V. van Driel,A. Smirl

DOI: https://doi.org/10.1364/IQEC.2004.ITUN5

2004-05-21

Abstract:We use pump-probe experiments to demonstrate that the spin polarization of electrons photogenerated in bulk GaAs by two-photon absorption of circularly polarized light is not significantly larger than by one-photon absorption, in agreement with theory

What problem does this paper attempt to address?

Clinical Characteristics, Disease Course, and Outcomes of Paediatric Patients with Myelin Oligodendrocyte Glycoprotein-Ab Associated Disease: A Retrospective Clinical Study

Min Zhang,Xiaonan Du,Shuizhen Zhou,Gang Pan,Jin Shen,Wenhui Li,Lifei Yu,Yuanfeng Zhou,Yunjian Zhang,Yi Wang,Linmei Zhang

DOI: https://doi.org/10.1016/j.jocn.2021.09.035

IF: 2.116

2021-01-01

Journal of Clinical Neuroscience

Abstract:Objective: To delineate the outcomes of paediatric patients with myelin oligodendrocyte glycoprotein antibody disease (MOGAD). Methods: We retrospectively analyzed the clinical characteristics, treatment, and outcomes of 34 paediatric patients with MOGAD from July 2015 to January 2020. Results: The median age at disease onset was 75.5 months (range: 19-170 months). The female-to-male ratio was 1:1.1. The median follow-up duration was 34.5 months (range: 14-63 months). Acute disseminated encephalomyelitis (ADEM) was the most common initial phenotype (52.9%), followed by optic neuritis (ON) (20.6%). Children with ADEM were younger than those with ON (P = 0.045). Twentyeight (82.4%) and 18 (56.3%) children had abnormal brain and spinal magnetic resonance imaging, respectively, during the first acute attack. MOG-abs titers in children with ON were statistically higher than those in children with ADEM (P = 0.04). Thirty-two children accepted glucocorticoid treatment, while 33 (97%) children demonstrated clinical improvement within 1 week, 21 children (61.8%) achieved clinical recovery within 1 month. Eight children (23.5%) suffered a relapse, the median interval between the initial attack and recurrence was 13 (range: 3-36) months. We detected neurological sequelae in seven (20.6%) children, with visual dysfunction being the most common sequela (85.7%). Conclusion: ADEM was the most common phenotype in both monophasic and relapsed paediatric MOGAD, followed by ON. Majority of pediatric MOGAD patients were highly responsive to glucocorticoid. Despite a benign prognosis in most patients, some patients endure neurological sequelae, mainly visual impairment. Patients with initial visual impairment should be carefully evaluated and administered individualized immunotherapy. (c) 2021 Elsevier Ltd. All rights reserved.
Clinical Characteristics and Associated Factors of Pediatric Acute Disseminated Encephalomyelitis Patients with MOG Antibodies: a Retrospective Study in Hangzhou, China.

Jue Shen,Donghui Lin,Tiejia Jiang,Feng Gao,Kewen Jiang

DOI: https://doi.org/10.1186/s12883-022-02963-0

2022-01-01

BMC Neurology

Abstract:Abstract Background To explore the clinical characteristics and related factors of children with acute disseminated encephalomyelitis (ADEM) with positive anti-myelin oligodendrocyte glycoprotein (MOG) antibody. Methods A retrospective study was conducted and enrolled pediatric ADEM patients who underwent serum MOG antibody detection from May 2017 to August 2020. The patients were divided into two groups: MOG- immunoglobulin G (IgG) positive (n = 35) and MOG-IgG negative (n = 50). We analyzed the clinical characteristics of MOG-IgG-positive ADEM pediatric patients and conducted a comparative analysis between the two groups. Results Thirty-five patients (21 males and 14 females) in the MOG-IgG-positive group with encephalopathy, multifocal neurological symptoms, and typical magnetic resonance imaging (MRI) abnormalities were enrolled. They usually had a favorable outcome, while some suffered from relapse. Compared to the MOG-IgG-negative group, MOG-IgG-positive ADEM patients had a longer disease duration (median: 10 vs. 6 days), more meningeal involvement (31.4% vs. 8%) and frontal lobe involvement (82.8% vs. 68%), higher relapse rates (14.3% vs. 2%), lower serum tumor necrosis factor (1–12.4 pg/ml, median 1.7 vs. 1–34 pg/ml, median 2.2) and interferon-gamma (1–9.4 pg/ml, median 1.3 vs. 1–64 pg/ml, median 3) (P < 0.05, respectively). Multivariate logistic regression analysis showed that the longer disease duration, meningeal involvement and frontal lobe involvement were the correlated factors of patients with ADEM with MOG antibody (P < 0.05). Conclusions Our findings provide clinical evidence that MOG-IgG positivity is associated with longer disease duration, meningeal involvement, and frontal lobe involvement.
Predictors of a relapsing course in myelin oligodendrocyte glycoprotein antibody-associated disease

Akash Virupakshaiah,Vinicius A Schoeps,Jonathan Race,Michael Waltz,Siefaddeen Sharayah,Zahra Nasr,Carson E Moseley,Scott S Zamvil,Cristina Gaudioso,Allison Schuette,Theron Charles Casper,John Rose,Eoin P Flanagan,Moses Rodriguez,Jan-Mendelt Tillema,Tanuja Chitnis,Mark P Gorman,Jennifer S Graves,Leslie A Benson,Mary Rensel,Aaron Abrams,Lauren Krupp,Timothy E Lotze,Gregory Aaen,Yolanda Wheeler,Teri Schreiner,Amy Waldman,Janet Chong,Soe Mar,Emmanuelle Waubant

DOI: https://doi.org/10.1136/jnnp-2024-333464

2024-07-04

Abstract:Background Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is a recently described demyelinating disorder, and children represent about 50% of all cases. Almost half of the patients experience relapses, but very few studies have evaluated predictors of relapse risk, challenging clinical management. The study aimed to identify predictors at MOGAD onset that are associated with a relapsing course. Methods Prospectively collected data from paediatric patients with MOGAD seen by the US Network of Paediatric MS Centres were leveraged. Univariable and adjusted multivariable models were used to predict recurrent disease. Results We identified 326 MOGAD cases (mean age at first event 8.9 years [SD 4.3], 57% female, 77% white and 74% non-Hispanic) and 46% relapsed during a mean follow-up of 3.9 years (SD 4.1). In the adjusted multivariable model, female sex (HR 1.66, 95% CI 1.17 to 2.36, p=0.004) and Hispanic/Latino ethnicity (HR 1.77, 95% CI 1.19 to 2.64, p=0.005) were associated with a higher risk of relapsing MOGAD. Maintenance treatment initiated before a second event with rituximab (HR 0.25, 95% CI 0.07 to 0.92, p=0.037) or intravenous immunoglobulin (IVIG) (HR 0.35, 95% CI 0.14 to 0.88, p=0.026) was associated with lower risk of a second event in multivariable analyses. Conversely, maintenance steroids were associated with a higher estimated relapse risk (HR 1.76, 95% CI 0.90 to 3.45, p=0.097). Conclusion Sex and ethnicity are associated with relapsing MOGAD. Use of rituximab or IVIG therapy shortly after onset is associated with a lower risk of the second event. Preventive treatment after a first event could be considered for those with a higher relapse risk.

surgery,psychiatry,clinical neurology
Do early relapses predict the risk of long‐term relapsing disease in an adult and paediatric cohort with MOGAD?

Bo Chen,Enrique Gomez‐Figueroa,Vyanka Redenbaugh,Anna Francis,Chanjira Satukijchai,Yan Wu,Silvia Messina,Mario Sa,Mark Woodhall,Neil P. Robertson,Ming Lim,Evangeline Wassmer,Rachel Kneen,Saif Huda,Camilla Blain,Christopher Halfpenny,Cheryl Hemingway,Eoin O'Sullivan,Jeremy Hobart,Leonora K. Fisniku,Roswell J. Martin,Ruth Dobson,Sarah A. Cooper,Victoria Williams,Patrick Waters,John J. Chen,Sean J. Pittock,Sithara Ramdas,Maria Isabel Leite,Eoin P. Flanagan,Ruth Geraldes,Jacqueline Palace

DOI: https://doi.org/10.1002/ana.26731

IF: 11.2

2023-07-03

Annals of Neurology

Abstract:Objective Myelin oligodendrocyte glycoprotein antibody‐associated disease (MOGAD) can be monophasic or relapsing, with early relapse being a feature. However, the relevance of early relapse on longer‐term relapse risk is unknown. Here, we investigate whether early relapses increase longer‐term relapse risk in MOGAD patients. Methods A retrospective analysis of 289 adult‐ and paediatric‐onset MOGAD patients followed for at least 2 years in 6 specialised referral centres. 'Early relapses' were defined as attacks within the first 12 months from onset, with 'very early relapses' defined within 30‐90 days from onset and 'delayed early relapses' defined within 90‐365 days. 'Long‐term relapses' were defined as relapses beyond 12 months. Cox regression modelling and Kaplan‐Meier survival analysis were used to estimate the long‐term relapse risk and rate. Results Sixty‐seven patients (23.2%) had early relapses with a median number of 1 event. Univariate analysis revealed an elevated risk for long‐term relapses if any 'early relapses' were present (hazard ratio [HR] 2.11, p<0.001), whether occurring during the first 3 months (HR 2.70, p<0.001) or the remaining 9 months (HR 1.88, p=0.001), with similar results yielded in the multivariate analysis. In children with onset below aged 12 years, only delayed early relapses were associated with an increased risk of long‐term relapses (HR 2.64, p=0.026). Interpretation The presence of very early relapses and delayed early relapses within 12 months of onset in MOGAD patients increases the risk of long‐term relapsing disease, while a relapse within 90 days appears not to indicate a chronic inflammatory process in young paediatric‐onset disease. This article is protected by copyright. All rights reserved.

neurosciences,clinical neurology
Predictors of relapsing disease course following index event in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD)

Negar Molazadeh,Philippe A. Bilodeau,Rebecca Salky,Gauruv Bose,Itay Lotan,Gabriela Romanow,Monique R. Anderson,Marcelo Matiello,Tanuja Chitnis,Michael Levy

DOI: https://doi.org/10.1016/j.jns.2024.122909

IF: 4.4

2024-01-31

Journal of the Neurological Sciences

Abstract:Background Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is an autoimmune disease that can present as a monophasic or relapsing disease course. Here, we investigate the predictors of developing relapsing disease with a focus on the index event. Methods MOGAD patients followed at Massachusetts General Hospital and Brigham and Women's Hospital were included. Data on demographic, clinical, and laboratory features were collected. Time-to-event survival analysis was performed using a Cox proportional hazards model. Univariate and multivariate regression analyses were performed. Results We included 124 patients with a diagnosis of MOGAD of which 62.1% ( n = 77) were female. The median (IQR) onset age and follow-up time were 31 (16–45), and 4.08 (2.2,7.9) years respectively. In total, 40.3% ( n = 50) of patients remained monophasic and, 59.7% ( n = 74) developed a relapsing course. The median (IQR) time between the index event and the second attack was 3(2, 13.7) months. Starting maintenance therapy following the index event was associated with decreased risk of relapsing disease (HR:0.26; 95%CI: 0.12, 0.54; P < 0.001). Maintenance therapy with Intravenous immunoglobulin (HR:0.1; 95% CI:0.01, 0.78, P = 0.02), rituximab (HR: 0.21; 95%CI: 0.08, 0.55; P = 0.001), and mycophenolate mofetil (HR: 0.27; 95%CI: 0.09, 0.77; P = 0.01) was associated with a decreased risk of relapsing disease course. A polyphasic first attack (HR:2.4;95%CI:1.31, 4.4; P = 0.004) and high CSF protein (HR:2.06; 95%CI: 1.01, 4.16; P = 0.04) were associated with a relapsing course. Conclusions In MOGAD patients, starting maintenance therapy following the index event reduces the risk of relapsing disease regardless of age, sex, and onset phenotype, while polyphasic first attack, and elevated CSF protein predict relapsing disease course.

neurosciences,clinical neurology
Early Maintenance Treatment Initiation and Relapse Risk Mitigation After a First Event of MOGAD in Adults: The MOGADOR2 Study

Romain Deschamps,Jessica Guillaume,Jonathan Ciron,Bertrand Audoin,Aurélie Ruet,Elisabeth Maillart,Julie Pique,Lakhdar Benyahya,David A Laplaud,Laure Michel,Nicolas Collongues,Mikael Cohen,Xavier Ayrignac,Eric Thouvenot,Helene Zephir,Bertrand Bourre,Caroline Froment Tilikete,Thibault Moreau,Paul Cantagrel,Philippe Kerschen,Sebastien Cabasson,Nicolas Maubeuge,Karolina Hankiewicz,Chantal Nifle,Eric Berger,Hana Megherbi,Laurent Magy,Frederic Klapczynski,Mariana Sarov Riviere,Claire Giannesini,Lorraine Hamelin,Marianne Giroux,Pierre Branger,Aude Maurousset,Guillaume Mathey,Maximilien Moulin,Nicolas Mélé,Caroline Papeix,Romain Marignier,as the NOMADMUS study group

DOI: https://doi.org/10.1212/WNL.0000000000209624

IF: 9.9

2024-08-13

Neurology

Abstract:Background and objectives: Because myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is a recently identified autoimmune disorder, the natural history of MOGAD is still not well described. The objective of this study was to describe the long-term outcomes of adult patients with MOGAD. In addition, we aimed to identify factors affecting relapse risk and neurologic outcomes. Methods: Clinical and biological data were obtained from patients with a first event of MOGAD and included in the French nationwide incident cohort between February 2014 and March 2017. Only patients aged 18 years or older at disease onset and with observation period of at least 3 months were included. Data were collected prospectively until July 2023 and registered in the dedicated French nationwide database. This form includes every relapse with phenotype description during follow-up, date of last assessment, final clinical outcome with Expanded Disability Status Scale score and visual acuity, and maintenance therapy. The probability of recurrence-free survival was assessed using the Kaplan-Meier method. Results: We included 128 patients. The onset phenotype was isolated optic neuritis in 81 patients (63.3%) and isolated myelitis in 25 patients (19.5%). The median follow-up duration was 77.8 months (range 3.2-111.2), with 49 patients (38.3%) experienced at least one relapse. Median times from onset to second and third attacks were 3.2 (1.0-86.2) and 13.0 (2.6-64.4) months, respectively. At the last assessment, Expanded Disability Status Scale Score was ≥3 and ≥6 in 22 (17.2%) and 6 (4.7%) patients, respectively. Eighty patients received at least one maintenance treatment. This treatment was initiated after the first attack in 47 patients (36.7% of the whole cohort) and at the time of a second attack in 25 (19.5%). Multivariate analysis revealed that initiating maintenance treatment after the first attack was associated with a lower relapse risk (OR = 0.26 [95% CI 0.11-0.62], p = 0.002). In patients receiving maintenance therapy after first attack, the 2-year, 4-year, 6-year, and 8-year relapse risks were 11%, 15%, 20%, and 20%, respectively. In other patients, the risks were 41%, 46%, 51%, and 56%. Discussion: The highest risk of a relapse in MOGAD occurs early, and initiating maintenance therapy from the first attack substantially reduced the relapse risk. Classification of evidence: This study provides Class III evidence that initiating maintenance therapy from the first attack in patients with MOGAD reduces the relapse risk.
The Saccharomyces cerevisiae SOM1 gene: heterologous complementation studies, homologues in other organisms, and association of the gene product with the inner mitochondrial membrane.

M. Bauerfeind,K. Esser,G. Michaelis

Abstract:The small nuclear gene SOM1 of Saccharomyces cerevisiae was isolated as a multicopy suppressor of a mutation in the IMP1 gene, which encodes the mitochondrial inner membrane peptidase subunit 1 (Imp1). Analysis revealed that Som1 and Imp1 are components of a mitochondrial protein export system, and interaction between these two proteins is indicated by the genetic suppression data. Here we describe the identification of a gene from Kluyveromyces lactis, which restores respiratory function to a S. cerevisiae SOM1 deletion mutant at 28 degrees C. The sequence of the K. lactis gene predicts a protein product of 8.1-kDa, comprising 71 amino acid residues, with a putative mitochondrial signal sequence at its N-terminus. The protein is 50% identical to its S. cerevisiae counterpart. The expression pattern of a homologous sequence in Leishmania major suggests a more general role for SOM1 in mitochondrial biogenesis and protein sorting. The various Som1 proteins exhibit a highly conserved region and a remarkable pattern of cysteine residues. A protein of the expected size was transcribed and translated in vitro. The Som1 protein was detected in fractions of S. cerevisiae enriched for mitochondria and found to be associated with the inner mitochondrial membrane.
Timing of Immunotherapeutic Strategies for First-Episode Isolated Anti-Myelin Oligodendrocyte Glycoprotein-IgG Associated Optic Neuritis: A Single-Centre Retrospective Study

Juan Zhao,Chao Meng,Hanqiu Jiang,Chuntao Lai,Yanjun Guo,Liping Zhu,Jiawei Wang

DOI: https://doi.org/10.1016/j.heliyon.2024.e33263

IF: 3.776

2024-01-01

Heliyon

Abstract:Background: There is no consensus on the timing of immunotherapeutic strategies for the first-episode anti-myelin oligodendrocyte glycoprotein-IgG (MOG-IgG) associated disorders (MOGAD) presenting with isolated optic neuritis (ON). Objective: To investigate the optimal timing of intravenous methylprednisolone therapy (IVMP) and necessity of immunosuppressive therapy for the first-episode isolated MOG-IgG associated ON (iMOG-ON). Methods: Adult patients with the first-episode iMOG-ON were enrolled. Primary outcomes were best-corrected visual acuity (BCVA) at last follow-up (i.e. final BCVA) and relapse, and their predictors were assessed by multivariate analysis. Results: 62 patients were included. Logistic regression analysis revealed BCVA at the time of IVMP (odds ratio: 0.463 (95 % confidence interval (CI) 0.310-0.714) was a factor predictive of regaining a final BCVA of 0.0 logMAR vision, and its Youden optimal criterion was <0.175 logMAR by plotting the receiver operating characteristic curve. The time-dependent cox proportional hazards model exhibited MMF therapy was not associated with a high likelihood of relapse-free survival (HR = 1.099, 95 % CI 0.892–1.354, P = 0.376) after adjusting for age of onset, gender, and baseline MOG serum titers. Similar analysis exhibited evidently negative association between high MOG-IgG serum titers at baseline and relapse-free survival after adjusting for age of onset, gender, and MMF therapy (HR = 0.339, 95 % CI 0.155–0.741, P = 0.007). Conclusions: During the first episode of iMOG-ON, the optimal timing of IVMP may be a short timeframe before visual acuity decreasing to 0.175 logMAR, and MMF therapy may not be recommended for patients with low MOG-IgG serum titers. Further long-term follow-up studies are required to validate these findings.
The MOG antibody non-P42 epitope is predictive of a relapsing course in MOG antibody-associated disease

Ganesha Liyanage,Benjamin P Trewin,Joseph A Lopez,Jane Andersen,Fiona Tea,Vera Merheb,Kristy Nguyen,Fiona X Z Lee,Marzena J Fabis-Pedrini,Alicia Zou,Ali Buckland,Anthony Fok,Michael H Barnett,Stephen W Reddel,Romain Marignier,Aseel El Hajj,Mastura Monif,Anneke van der Walt,Jeannette Lechner-Scott,Allan G Kermode,Tomas Kalincik,Simon A Broadley,Russell C Dale,Sudarshini Ramanathan,Fabienne Brilot

DOI: https://doi.org/10.1136/jnnp-2023-332851

2024-01-30

Abstract:Background Myelin oligodendrocyte glycoprotein (MOG) IgG seropositivity is a prerequisite for MOG antibody-associated disease (MOGAD) diagnosis. While a significant proportion of patients experience a relapsing disease, there is currently no biomarker predictive of disease course. We aim to determine whether MOG-IgG epitopes can predict a relapsing course in MOGAD patients. Methods MOG-IgG-seropositive confirmed adult MOGAD patients were included (n=202). Serum MOG-IgG and epitope binding were determined by validated flow cytometry live cell-based assays. Associations between epitopes, disease course, clinical phenotype, Expanded Disability Status Scale and Visual Functional System Score at onset and last review were evaluated. Results Of 202 MOGAD patients, 150 (74%) patients had MOG-IgG that recognised the immunodominant proline42 (P42) epitope and 115 (57%) recognised histidine103/serine104 (H103/S104). Fifty-two (26%) patients had non-P42 MOG-IgG and showed an increased risk of a relapsing course (HR 1.7; 95% CI 1.15 to 2.60, p=0.009). Relapse-freedom was shorter in patients with non-P42 MOG-IgG (p=0.0079). Non-P42 MOG-IgG epitope status remained unchanged from onset throughout the disease course and was a strong predictor of a relapsing course in patients with unilateral optic neuritis (HR 2.7, 95% CI 1.06 to 6.98, p=0.038), with high specificity (95%, 95% CI 77% to 100%) and positive predictive value (85%, 95% CI 45% to 98%). Conclusions Non-P42 MOG-IgG predicts a relapsing course in a significant subgroup of MOGAD patients. Patients with unilateral optic neuritis, the most frequent MOGAD phenotype, can reliably be tested at onset, regardless of age and sex. Early detection and specialised management in these patients could minimise disability and improve long-term outcomes.

surgery,psychiatry,clinical neurology
[Clinical Follow-Up Study of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease in Children].

X L Teng,J Zhang,X T Chang,S R Li,J Zhou,Y H Zhang,X H Bao,Y W Jiang,Y Wu

DOI: https://doi.org/10.3760/cma.j.cn112140-20210703-00549

2021-01-01

Abstract:Objective: To summarize the clinical characteristics of myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) and compare the differences in efficacy of different disease-modifying drugs. Methods: An ambispective cohort study was conducted in 42 children diagnosed with MOGAD at Department of Pediatrics, Peking University First Hospital from January 2012 to March 2021 and conducted long-term follow-up to analyze clinical phenotypes and compare the efficacy of different disease-modifying drugs such as rituximab, mycophenolate mofetil and azathioprine. Kruskal-Wallis H test was used to compare the annual relapse rate of disease-modifying drugs at different times, expanded disability status scale (EDSS) score at the last follow-up, and Wilcoxon rank test was used to compare the annual relapse rate before and after modified disease therapy. The Log-rank (Mantel-Cox) survival curve was used to compare the relapse rate of different disease-modifying drugs. Results: Of the 42 cases, 22 were male and 20 were female, with the age at disease onset of 5.96 (2.33-12.90) years. The disease duration was 4.46 (1.25-13.00) years at the last follow-up with 161 clinical acute attacks. Acute disseminated encephalomyelitis (ADEM) was the most common phenotype of first attack and all attacks during disease course ((60% (25/42) for first attack, 38% (61/161) for all attacks). The most common clinical syndrome was neuromyelitis optica spectrum disorders (NMOSD) (50%, 21/42). Of the 42 children, 5 (12%) showed encephalitis and 6 (14%) combined with anti-N-methyl-D-aspartate receptor (NMDAR) antibody overlap syndrome. The most commonly involved areas of brain magnetic resonance imaging (MRI) were subcortical white matter (71%, 88/124), cortex (26%, 32/124) and periventricular white matter (25%, 32/124). Spinal cord MRI was most frequently involved in cervical (70%, 16/23) and thoracic (61%, 14/23) medulla, and 43% (10/23) longitudinally extensive transeverse myelitis. Disease-modifying drugs were used in 34 patients. The annual relapse rate after treatment with rituximab, mycophenolate mofetil and azathioprine decreased (all P<0.05) and there was no statistically significant difference in the annual relapse proportion among the groups (P=0.307). Conclusions: The most common clinical attack of first and all of MOGAD in children is ADEM, and the most common clinical syndrome is NMOSD. Rituximab, mycophenolate mofetil and azathioprine can reduce the annual relapse rate, but it is not clear effect of which treatment is better.
Clinical analysis of myelin oligodendrocyte glycoprotein antibody-associated disease in a diverse cohort of children: A single-center observational study

Linda Nguyen,Cynthia X Wang,Roberto S Hernandez,Benjamin M Greenberg,Cynthia X. Wang,Roberto S. Hernandez,Benjamin M. Greenberg

DOI: https://doi.org/10.1016/j.msard.2024.105497

IF: 4.808

2024-04-01

Multiple Sclerosis and Related Disorders

Abstract:BACKGROUND: Prognostic markers for relapse and neurological disability following the first clinical event in children with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) remain lacking. We investigated the clinical profiles and early prognostic factors associated with relapsing disease or impaired functional outcome in a large single-center cohort of pediatric MOGAD.METHODS: We retrospectively analyzed the clinical and paraclinical data and treatment outcomes of children with MOGAD seen at Children's Health in Dallas, Texas from 2009 to 2022. Univariate analyses were used to evaluate factors from initial event associated with relapsing disease course and impaired functional outcome (modified Rankin scale [mRS] >1) at final follow-up.RESULTS: Our cohort comprised of 87 children of diverse race/ethnicity. Presentation with acute disseminated encephalomyelitis (ADEM) was more frequent in children aged ≤8 years and Caucasian background, whereas presentation with optic neuritis was more common in children aged >8 years and other race/ethnicity. 44.3 % (27/61) had relapsing disease course, of whom 48.0 % had multiple relapses. 30.3 % (23/76) had final mRS >1. Children with abnormal electroencephalogram had reduced relapse risk. Children with ADEM presentation, severe disease, low MOG-IgG titer, and central and systemic inflammation (represented by cerebrospinal fluid pleocytosis and serum leukocytosis, respectively) at onset had higher likelihood of final mRS >1.CONCLUSION: Abnormal electroencephalogram at the first event was associated with reduced relapse risk while disease severity and peripheral inflammation significantly contributed to final neurological disability. Further studies are needed to validate these findings as early risk factors for disability and relapse and to identify optimal treatment strategies.

clinical neurology
The clinical relevance of MOG antibody testing in cerebrospinal fluid

Molly Reynolds,Irene Tan,Kristy Nguyen,Vera Merheb,Fiona X Z Lee,Benjamin P Trewin,Magdalena Lerch,Snehal Shah,Nigel Wolfe,Katherine Buzzard,Jeannette Lechner-Scott,Marzena Fabis-Pedrini,Anthony Fok,Nevin John,Chris Kneebone,Con Yiannikas,David A Brown,Allan G Kermode,Stephen Reddel,Russell C Dale,Fabienne Brilot,Sudarshini Ramanathan,Australasian MOGAD Study Group,Robert Adam,Jane Andersen,Ian Andrews,Jayne Antony,Patrick Aouad,Monica Badve,Michael H Barnett,Joshua Barton,Heidi Beadnall,Stefan Blum,Michael Boggild,Simon Broadley,Jim Burrow,Helmut Butzkueven,Ann Bye,Anita Cairns,Sophie Calvert,Fiona Chan,Shabeed Chelakkadan,Melissa Chu,Damian R Clark,Isabella Cotter,Fionna Dela Cruz,Marzena J Fabis-Pedrini,Deborah Field,Clare L Fraser,Victor S C Fung,Justin Garber,Serge Geara,Deepak Gill,Sachin Gupta,Todd A Hardy,Simon Hawke,Andrew P D Henderson,Niroshan Jeyakumar,Nevin A John,Dean L Jones,Hannah F Jones,Tomas Kalincik,Allan Kermode,Matthew Kiernan,Trevor Kilpatrick,Andrew J Kornberg,Mitchell Lawlor,Richard J Leventer,Vivien Li,Simon Ling,Ganesha Liyanage,Joseph A Lopez,Kit Kwan Margaret Ma,Stephen Malone,Mark P Marriot,Pamela McCombe,Alan McDougall,Manoj P Menezes,Christina Miteff,Mastura Monif,Gopinath Musuwadi Subramanian,Ai-Lan Nguyen,Gina O'Grady,John O'Neill,Robert Ouvrier,Mark Paine,John Parratt,Sekhar Pillai,Jane Prosser,Jessica Qiu,Sean Ds Riminton,Izanne Roos,Jennifer Sandbach,Ingrid E Scheffer,Ubaid Shah,Neil Shuey,Adriane Sinclair,Pakeeran Siriratnam,Mark Slee,Claire G Spooner,Ian Sutton,Sanjay Swaminathan,Esther Tantsis,James Thomas,Terrence Thomas,Julia Thompson,Christopher Troedson,Anneke Van der Walt,Steve Vucic,Justine Wang,Tyson Ware,Richard Webster,Ming Wei Lin,Owen White,Wei Yeh,Eppie M Yiu,Michael Zhong

DOI: https://doi.org/10.1002/acn3.52163

2024-07-28

Abstract:Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is diagnosed by serum MOG-immunoglobulin G (MOG-IgG) in association with typical demyelination. 111/1127 patients with paired CSF/serum samples were seropositive for MOG-IgG. Only 7/1016 (0.7%) seronegative patients had CSF-restricted MOG-IgG. While 3/7 patients had longitudinally extensive transverse myelitis, four had a confirmed alternate diagnosis (three multiple sclerosis, one CNS vasculitis). In a national referral setting, CSF-restricted MOG-IgG had a low sensitivity (2.63%, 95%CI 0.55-7.50%) and low positive predictive value (1.97%, 95%CI 0.45-8.13%). We strongly recommend serum as the preferred diagnostic biospecimen, and urge caution in the interpretation of CSF-restricted MOG-IgG in patients without clinico-radiological features consistent with MOGAD.
Blood neutrophils, oligoclonal bands and bridging corticosteroids as predictive factors for MOGAD course: Insights from a multicentric Portuguese cohort

Ana Lídia Neves,Andrea Cabral,Catarina Serrão,Daniela Santos Oliveira,Janice Alves,José Miguel Alves,Mafalda Soares,Ernestina Santos,Mafalda Seabra,Helena Felgueiras,João Ferreira,Eva Brandão,Rui Guerreiro,Carla Cecília Nunes,Filipa Ladeira,José Vale,Maria José Sá,André Jorge

DOI: https://doi.org/10.1016/j.msard.2024.105935

IF: 4.808

2024-10-12

Multiple Sclerosis and Related Disorders

Abstract:Background Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD) is a heterogeneous entity with either a monophasic or relapsing course. Well-established predictors of relapsing disease are lacking. Objective Identifying predictors of relapsing MOGAD, particularly at disease onset. Methods A multicentre observational retrospective study was conducted to characterise a cohort of Portuguese adult MOGAD patients. Patients were identified from participating centre databases. Clinical and demographic data were collected from medical records. Bivariate analysis was conducted to compare patients with relapsing and monophasic MOGAD. Significant variables were included in a stepwise multiple regression analysis to identify independent predictors of relapse. Results Eighty-seven MOGAD patients from 8 public hospitals were included. Relapsing MOGAD was found in 35.6% (n=31). Mean diagnostic delay was 3.2 (±6.2) years and time to relapse was 4.4 (±6.4) years. Multiple logistic regression showed that higher neutrophil count (p<0.01), presence of oligoclonal bands (p=0.025) and no bridging corticosteroids (p=0.038) at first attack were predictive of relapsing MOGAD. Conclusion Neutrophil count and oligoclonal bands at first attack may facilitate early decision-making regarding maintenance immunotherapy. Bridging corticosteroids may also influence the course of MOGAD. Further studies with prospective design are warranted.

clinical neurology
Disease Course and Treatment Responses in Children With Relapsing Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease

Yael Hacohen,Yu Yi Wong,Christian Lechner,Maciej Jurynczyk,Sukhvir Wright,Bahadir Konuskan,Judith Kalser,Anne Lise Poulat,Helene Maurey,Esther Ganelin-Cohen,Evangeline Wassmer,Chery Hemingway,Rob Forsyth,Eva Maria Hennes,M. Isabel Leite,Olga Ciccarelli,Banu Anlar,Rogier Hintzen,Romain Marignier,Jacqueline Palace,Matthias Baumann,Kevin Rostásy,Rinze Neuteboom,Kumaran Deiva,Ming Lim

DOI: https://doi.org/10.1001/jamaneurol.2017.4601

IF: 29.907

2018-04-01

JAMA Neurology

Abstract:Importance: Myelin oligodendrocyte glycoprotein antibodies (MOG-Abs) are consistently identified in a range of demyelinating disorders in adults and children. Current therapeutic strategies are largely center specific, and no treatments have been formally evaluated.Objective: To examine the clinical phenotypes, treatment responses, and outcomes of children with relapsing MOG-Ab-associated disease.Design, Setting, and Participants: This study prospectively collected demographic, clinical, and radiologic data from 102 patients from 8 countries of the EU Paediatric Demyelinating Disease Consortium from January 1, 2014, through December 31, 2016. Patients were treated according to local protocols.Main Outcomes and Measures: Annualized relapse rates (ARRs) and Expanded Disability Status Scale (EDSS) scores before and during treatment with disease-modifying drugs (DMDs).Results: A total of 102 children were identified (median [range] age, 7.0 [1.5-7.9] years; male to female ratio, 1.0:1.8; white to other race/ethnicity ratio, 3.6:1.0). Original diagnoses were neuromyelitis optica spectrum disorder (44 patients [43.1%]), acute disseminated encephalomyelitis followed by optic neuritis (20 [19.6%]), multiphasic disseminated encephalomyelitis (20 [19.6%]), and relapsing optic neuritis (18 [17.6%]). In all, 464 demyelinating events were reported. Treated patients had more relapses (median, 3.0; range, 1.0-17.0) than untreated patients (median, 1.0; range 1.0-7.0) (P = .009) and higher EDSS scores (median, 1.5; interquartile range, 0-2.5) than untreated patients (median, 1.0; interquartile range, 0-1.5) (P < .001). Fifty-two children (51.0%) received DMDs: 28 (53.8%) were treated with 1 DMD, 17 (32.7%) with 2, and 7 (13.5%) with 3 or more sequential DMDs. Patients relapsed during all treatments, with a total of 127 relapses on treatment reported. No changes in median ARR and EDSS score were observed between the preinitiation and postinitiation phases of interferon beta and glatiramer acetate treatment (n = 11). The median ARR was reduced from 1.84 to 1.0 with azathioprine (n = 20, P < .001), 1.79 to 0.52 with mycophenolate mofetil (n = 15, P = .003), and 2.12 to 0.67 with rituximab (n = 9, P < .001), although the median EDSS score remained unchanged. An improvement in ARR (from 2.16 to 0.51, P < .001) and EDSS score (from 2.2 to 1.2, P = .01) was observed in the 12 patients treated with regular intravenous immunoglobulins.Conclusions and Relevance: Although commonly used to treat patients with multiple sclerosis, DMDs were not associated with clinical improvement in children with MOG-Ab-associated disease, whereas azathioprine, mycophenolate mofetil, rituximab, and particularly intravenous immunoglobulins were associated with a reduction in relapse frequency. A correct diagnosis of relapsing MOG-Ab-associated disorders is therefore important to optimize immune treatment.

clinical neurology
Criteria for Myelin Oligodendrocyte Glycoprotein Antibody‐associated Disease: Balancing Underdiagnosis with Overdiagnosis

Er-Chuang Li,Qi-Lun Lai,Meng-Ting Cai,Wei Fang,Mei-Ping Ding,Yin-Xi Zhang

DOI: https://doi.org/10.1002/ctd2.225

2023-01-01

Clinical and Translational Discovery

Abstract:Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD) is an immune-mediated inflammatory central nervous system (CNS) disease that has been gradually recognized in recent years and is currently considered as a distinct disease entity distinguished from multiple sclerosis and neuromyelitis optica spectrum disorder. Lately, the new diagnostic criteria for MOGAD proposed by the International MOGAD Panel were published.1 The new criteria cover six core clinical phenotypes (optic neuritis, myelitis, acute disseminated encephalomyelitis, cerebral monofocal or polyfocal deficits, brainstem or cerebellar deficits, and cerebral cortical encephalitis often with seizures), emphasize the positive serum MOG-immunoglobulin G (IgG) test (determined using cell-based assay) and exclusion of alternative causes, and include supporting clinical/neuroimaging features to offset possible deficiencies in antibody detection, aiming to provide precise diagnosis of MOGAD and avoid overdiagnosis. MOGAD, with diverse clinico-radiological manifestations, is deemed to be the “great mimic”. While the new diagnostic criteria may be relatively strict in clinical practice, we are concerned that some patients suffering from MOGAD may be omitted according to the current standards. For instance, some patients, who clearly tested positive for serum MOG-IgG, presented with fever, headache, and leptomeningeal enhancement on brain magnetic resonance imaging (MRI). In this clinical setting, MOG antibody-associated aseptic meningitis is the most reasonable diagnosis.2, 3 However, these patients are unlikely to be diagnosed with MOGAD according to the new criteria, given that meningitis does not fit into any of the six defined phenotype classifications. In another scenario, a few patients with seizures (a relatively common presentation in MOGAD4) may have normal brain MRI (especially at the disease onset),5 and may not sufficiently fulfil the new criteria, which can affect the early diagnosis of MOGAD, thus delaying immunotherapy. In addition, short segment myelitis (SSM, < 3 contiguous vertebral segments in length) is not uncommon in MOGAD. Ciron et al. evaluated 73 patients with MOGAD and found 28 (38.4%) had short lesions and 45 (61.6%) had long lesions at the first episode of myelitis.6 Moreover, the occurrence of conus medullaris involvement varied in different populations, which seems to be more uncommon in patients presenting in China (2/59 [3.4%]7), than those in Europe (22/73 [30.1%]6) and North America (21/51 [41.2%]8). Similarly, in our center with recent 5-year data, conus medullaris injury was observed in 2/17 [11.8%] cases with myelitis as the onset manifestation. SSM, with eccentric lesions and without conus medullaris involvement, can occur with low positive serum MOG-IgG. These patients would also fail to meet with the current criteria, but their clinical findings may still be relevant to MOG-IgG. Furthermore, MOG-IgG associated myelitis with negative initial spinal cord MRI occurred in 7/73 patients with MOGAD.9 For the patients with MRI-negative myelitis, if detected with low positive serum MOG-IgG, also challenge the diagnosis of MOGAD according to the new criteria, which may lead to the therapeutic dilemma. Moving forward, detailed studies of MOGAD are likely to identify additional clinico-radiological phenotypes, and the frequency of existing phenotypes will also change, and the diagnostic criteria need to be revised and updated with the times. Although there is still room for improvement, the publication of the 2023 criteria is a key step towards unifying and standardizing the diagnosis of MOGAD, pushing its research into a new era. We expect that the next version of MOGAD criteria will include the uncommon clinical phenotypes, which would allow clinicians to be more vigilant in identifying patients with MOGAD that are presenting with atypical manifestations. Furthermore, we suggest it would be beneficial to define levels of diagnostic certainty (such as possible/probable/definite MOGAD), similar to the diagnostic criteria for autoimmune encephalitis and paraneoplastic neurological syndromes. We believe that these approaches may be more advantageous in clinical diagnosis and management strategies, compensating for lower sensitivity from the current strict diagnostic criteria in the pursuit of higher specificity, so as to decrease underdiagnosis. Given that MOGAD is a treatable disease, but therapeutic regimens are still different from those for other inflammatory CNS diseases, early identification can facilitate timely and optimal treatment, thus improving the prognosis. Not applicable. The authors declare no conflict of interest. Not applicable. Data sharing is not applicable to this article as no new data were created or analyzed in this study.
Meta-analysis of the Effectiveness of Relapse Prevention Therapy for Myelin-Oligodendrocyte Glycoprotein Antibody-Associated Disease

Xuting Chang,Jie Zhang,Shangru Li,Pengxia Wu,Rui Wang,Chongfan Zhang,Ye Wu

DOI: https://doi.org/10.1016/j.msard.2023.104571

IF: 4.808

2023-01-01

Multiple Sclerosis and Related Disorders

Abstract:BACKGROUND:Approximately 40% of adults and 30% of children with Myelin-oligodendrocyte glycoprotein antibody-associated disease (MOGAD) experience a relapsing course, but the optimal relapse prevention therapy remains unclear. A meta- analysis was conducted to investigate the efficacy of azathioprine (AZA), mycophenolate mofetil (MMF), rituximab (RTX), maintenance intravenous immunoglobulin (IVIG), and tocilizumab (TCZ) in prevention of attacks in MOGAD.METHODS:English and Chinese-language articles published from January 2010 to May 2022 were searched in PubMed, Embase, Web of Science, Cochrane, Wanfang Data, China National Knowledge Infrastructure (CNKI), and China Science and Technology Journal Database (CQVIP). Studies with fewer than three cases were excluded. Meta-analysis of the relapse-free rate, the change of annualized relapse rate (ARR)and Expanded Disability Status Scale (EDSS) scores before and after treatment, and an age subgroup analysis was performed.RESULTS:A total of 41 studies were included. Three were prospective cohort studies, one was an ambispective cohort study, and 37 were retrospective cohort studies or case series. Eleven, eighteen, eighteen, eight, and two studies were included in the meta-analysis for relapse-free probability after AZA, MMF, RTX, IVIG, and TCZ therapy, respectively. The proportions of patients without relapse after AZA, MMF, RTX, IVIG, and TCZ were 65% [95% confidence interval (CI):49%-82%]), 73% (95%CI:62%-84%), 66% (95%CI:55%-77%), 79% (95%CI:66%-91%), and 93% (95%CI:54%-100%), respectively. The relapse-free rate did not significantly differ between the children and adults treated with each medication. Six, nine, ten, and three studies were included in the meta-analysis for the change of ARR before and after AZA, MMF, RTX, and IVIG therapy, respectively. ARR was significantly decreased after AZA, MMF, RTX, and IVIG therapy with a mean reduction of 1.58 (95%CI: [-2.29--0.87]), 1.32 (95%CI: [-1.57--1.07]), 1.01 (95%CI: [-1.34--0.67]), and 1.84 (95%CI: [-2.66--1.02]), respectively. The change in ARR did not significantly differ between children and adults.CONCLUSIONS:AZA, MMF, RTX, maintenance IVIG, and TCZ all reduce the risk of relapse in both pediatric and adult patients with MOGAD. The literatures included in the meta-analysis were mainly retrospective studies, so large randomized prospective clinical trials are needed to compare the efficacy of different treatments.
[Sedimentation and density distribution of virus-induced RNA in extracts of cells infected by Newcastle disease virus].

N. Kaverin,V. G. Zaslavskii,A. Bukrinskaia,V. Zaides,M. I. Volkova

Abstract:
Clinical presentation and prognosis in MOG-antibody disease: a UK study

Maciej Jurynczyk,Silvia Messina,Mark R Woodhall,Naheed Raza,Rosie Everett,Adriana Roca-Fernandez,George Tackley,Shahd Hamid,Angela Sheard,Gavin Reynolds,Saleel Chandratre,Cheryl Hemingway,Anu Jacob,Angela Vincent,M Isabel Leite,Patrick Waters,Jacqueline Palace

DOI: https://doi.org/10.1093/brain/awx276

IF: 14.5

2017-11-09

Brain

Abstract:See de Seze (doi:10.1093/brain/awx292) for a scientific commentary on this article. A condition associated with an autoantibody against MOG has been recently recognized as a new inflammatory disease of the central nervous system, but the disease course and disability outcomes are largely unknown. In this study we investigated clinical characteristics of MOG-antibody disease on a large cohort of patients from the UK. We obtained demographic and clinical data on 252 UK patients positive for serum immunoglobulin G1 MOG antibodies as tested by the Autoimmune Neurology Group in Oxford. Disability outcomes and disease course were analysed in more detail in a cohort followed in the Neuromyelitis Optica Oxford Service (n = 75), and this included an incident cohort who were diagnosed at disease onset (n = 44). MOG-antibody disease affects females (57%) slightly more often than males, shows no ethnic bias and typically presents with isolated optic neuritis (55%, bilateral in almost half), transverse myelitis (18%) or acute disseminated encephalomyelitis-like presentations (18%). In the total Oxford cohort after a median disease duration of 28 months, 47% of patients were left with permanent disability in at least one of the following: 16% patients had visual acuity ≤6/36 in at least one eye, mobility was limited in 7% (i.e. Expanded Disability Status Scale ≥ 4.0), 5% had Expanded Disability Status Scale ≥ 6.0, 28% had permanent bladder issues, 20% had bowel dysfunction, and 21% of males had erectile dysfunction. Transverse myelitis at onset was a significant predictor of long-term disability. In the incident cohort 36% relapsed after median disease duration of 16 months. The annualized relapse rate was 0.2. Immunosuppression longer than 3 months following the onset attack was associated with a lower risk of a second relapse. MOG-antibody disease has a moderate relapse risk, which might be mitigated by medium term immunosuppression at onset. Permanent disability occurs in about half of patients and more often involves sphincter and erectile functions than vision or mobility.

neurosciences,clinical neurology
Effectiveness and tolerability of different therapies in preventive treatment of MOG-IgG-associated disorder: A network meta-analysis

Xiaofei Wang,Lingyao Kong,Zhengyang Zhao,Ziyan Shi,Hongxi Chen,Yanlin Lang,Xue Lin,Qin Du,Hongyu Zhou

DOI: https://doi.org/10.3389/fimmu.2022.953993

2022-07-26

Abstract:Background: Immunotherapy has been shown to reduce relapses in patients with myelin oligodendrocyte glycoprotein antibody-associated disorder (MOG-AD); however, the superiority of specific treatments remains unclear. Aim: To identify the efficacy and tolerability of different treatments for MOG-AD. Methods: Systematic search in Pubmed, Embase, Web of Science, and Cochrane Library databases from inception to March 1, 2021, were performed. Published articles including patients with MOG-AD and reporting the efficacy or tolerability of two or more types of treatment in preventing relapses were included. Reported outcomes including incidence of relapse, annualized relapse rate (ARR), and side effects were extracted. Network meta-analysis with a random-effect model within a Bayesian framework was conducted. Between group comparisons were estimated using Odds ratio (OR) or mean difference (MD) with 95% credible intervals (CrI). Results: Twelve studies that compared the efficacy of 10 different treatments in preventing MOG-AD relapse, including 735 patients, were analyzed. In terms of incidence of relapse, intravenous immunoglobulins (IVIG), oral corticosteroids (OC), mycophenolate mofetil (MMF), azathioprine (AZA), and rituximab (RTX) were all significantly more effective than no treatment (ORs ranged from 0.075 to 0.34). On the contrary, disease-modifying therapy (DMT) (OR=1.3, 95% CrI: 0.31 to 5.0) and tacrolimus (TAC) (OR=5.9, 95% CrI: 0.19 to 310) would increase the incidence of relapse. Compared with DMT, IVIG significantly reduced the ARR (MD=-0.85, 95% CrI: -1.7 to -0.098). AZA, MMF, OC and RTX showed a trend to decrease ARR, but those results did not reach significant differences. The combined results for relapse rate and adverse events, as well as ARR and adverse events showed that IVIG and OC were the most effective and tolerable therapies. Conclusions: Whilst DMT should be avoided, IVIG and OC may be suited as first-line therapies for patients with MOG-AD. RTX, MMF, and AZA present suitable alternatives.
Development of a Simplified Design Formula for the Low Frequency Cut-Off of a Small Two Volume Silencer

D. T. Soedel,W. Soedel

Abstract:

Two-photon spin injection in semiconductor

Clinical Characteristics, Disease Course, and Outcomes of Paediatric Patients with Myelin Oligodendrocyte Glycoprotein-Ab Associated Disease: A Retrospective Clinical Study

Clinical Characteristics and Associated Factors of Pediatric Acute Disseminated Encephalomyelitis Patients with MOG Antibodies: a Retrospective Study in Hangzhou, China.

Predictors of a relapsing course in myelin oligodendrocyte glycoprotein antibody-associated disease

Do early relapses predict the risk of long‐term relapsing disease in an adult and paediatric cohort with MOGAD?

Predictors of relapsing disease course following index event in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD)

Early Maintenance Treatment Initiation and Relapse Risk Mitigation After a First Event of MOGAD in Adults: The MOGADOR2 Study

The Saccharomyces cerevisiae SOM1 gene: heterologous complementation studies, homologues in other organisms, and association of the gene product with the inner mitochondrial membrane.

Timing of Immunotherapeutic Strategies for First-Episode Isolated Anti-Myelin Oligodendrocyte Glycoprotein-IgG Associated Optic Neuritis: A Single-Centre Retrospective Study

The MOG antibody non-P42 epitope is predictive of a relapsing course in MOG antibody-associated disease

[Clinical Follow-Up Study of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease in Children].

Clinical analysis of myelin oligodendrocyte glycoprotein antibody-associated disease in a diverse cohort of children: A single-center observational study

The clinical relevance of MOG antibody testing in cerebrospinal fluid

Blood neutrophils, oligoclonal bands and bridging corticosteroids as predictive factors for MOGAD course: Insights from a multicentric Portuguese cohort

Disease Course and Treatment Responses in Children With Relapsing Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease

Criteria for Myelin Oligodendrocyte Glycoprotein Antibody‐associated Disease: Balancing Underdiagnosis with Overdiagnosis

Meta-analysis of the Effectiveness of Relapse Prevention Therapy for Myelin-Oligodendrocyte Glycoprotein Antibody-Associated Disease

[Sedimentation and density distribution of virus-induced RNA in extracts of cells infected by Newcastle disease virus].

Clinical presentation and prognosis in MOG-antibody disease: a UK study

Effectiveness and tolerability of different therapies in preventive treatment of MOG-IgG-associated disorder: A network meta-analysis

Development of a Simplified Design Formula for the Low Frequency Cut-Off of a Small Two Volume Silencer